Navigation Links
CardioInsight Announces Closing of $7.5 Million Equity Financing
Date:3/14/2012

CLEVELAND, March 14, 2012 /PRNewswire-USNewswire/ -- CardioInsight Technologies Inc., the leading developer of non-invasive electrocardiographic mapping technology, announced today the closing of a $7.5 million Series "C" financing.  The proceeds from the financing will help CardioInsight accelerate clinical and commercial efforts related to its ECVUEadvanced 3D cardiac mapping system. 

(Logo: http://photos.prnewswire.com/prnh/20110531/DC10432LOGO)

CardioInsight recently announced its CE Mark certification and the successful installation of the ECVUE System at its first clinical customer sites.  In the coming months, the Company will focus on securing its FDA regulatory clearance, demonstrating the value of the ECVUE System to improve the mapping of arrhythmias in routine clinical use, and proving its value in Cardiac Resynchronization Therapy (CRT).

"Securing this additional investment provides CardioInsight the ability to accelerate its clinical development and further demonstrate the commercial value of the ECVUE System," said Steve Arless, CEO of CardioInsight.  "Over the next twelve to eighteen months, we will present a growing body of evidence demonstrating the strong clinical utility of our system; ultimately laying the foundation for commercial expansion in Europe, and commercial introduction in the U.S."

CardioInsight has successfully completed commercial installations at three leading centers in Europe, including St. Mary's Hospital in London, England, the Kerckhoff Clinic in Bad Nauheim, Germany, and the Hopital Cardiologique du Haut-Leveque in Bordeaux, France.  This increased clinical use will highlight the ECVUE System's ability to simplify cardiac mapping procedures, reduce procedure time, and expand the use of mapping to new applications, including cardiac resynchronization for heart failure.

About CardioInsight Technologies Inc.

CardioInsight is commercializing a revolutionary technology that non-invasively generates 3D images of the electrical activity of the heart. 
The images help physicians more accurately treat certain heart ailments such as arrhythmias 
and congestive heart failure. The Company's ECVUE system non-invasively generates real-time, whole heart images of 
the electrical activity on the surface of the heart by combining body surface electrical data with
 3D anatomical data obtained from imaging scans. It then reconstructs and
 displays 3D images and other useful measures of cardiac electrical activity as if the
 measurements were taken directly from the surface of the heart. To date, CardioInsight has completed more than 400 patient studies at leading clinical centers in the United States and Europe, including the Cleveland Clinic Foundation, University Hospitals of Cleveland, Loyola University Medical Center, the University of Pennsylvania Medical Center, and the Hopital Cardiologique du Haut-Leveque in Bordeaux, France.  These studies address a broad variety of cardiac arrhythmias, as well as cardiac resynchronization therapy for congestive heart failure, demonstrating the unique clinical value of the ECVUE System.  Results of the studies have been published in leading peer-reviewed journals, and presented at international clinical conferences.  The Company has received its CE Mark and markets the ECVUE System in Europe.

For more information, visit CardioInsight's website at www.cardioinsight.com, or contact us at 216-453-5950.

 


'/>"/>
SOURCE CardioInsight Technologies Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CardioInsight Announces Addition of Jim Hassett to Senior Management Team
2. CardioInsight Announces CE Mark Clearance and European Launch of the ECVUE™ Non-Invasive Electrocardiographic Mapping System
3. Generex Subsidiary Antigen Express Announces Publication of Review Showcasing its Proprietary Therapeutic Vaccine Technology in the Journal Vaccine
4. Heborium Group Announces 23% Increase in 1st Quarter 2012 Revenue
5. S1 Pharmaceuticals Announces New Executive Management and Scientific Advisory Board Appointments
6. Sosei Announces Initiation of Phase I Study for SO-1105
7. Prime Therapeutics Announces CareCentered Contract™ with EMD Serono, Inc. for MS Drug Rebif®
8. ThermoGenesis Announces Webcast of Presentation at Roth Capital Conference
9. Patented Protection Against Counterfeit Pharmaceuticals and Retail Fraud. ICAP Patent Brokerage Announces for Auction a Patented System for Verification of Purchase and Product Legality
10. CVS Caremark Corporation Announces Quarterly Dividend
11. SIRO Clinpharm Announces Appointment of Gopakumar Menon as Chief Executive Officer to Lead the Global Clinical Research Organization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , May 25, 2016 Digital Health ... to it by the US Patent and Trademark ... technology includes proprietary processes for electronic opt-­in and ... and wellness programs, HIPAA compliance and otherwise. ... "Our technology allows for ...
(Date:5/25/2016)... PUNE, India , May 25, 2016 /PRNewswire/ ... Pipeline Review, H1 2016"market research report that provides ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ... releases. It also reviews key players involved in ...
(Date:5/24/2016)... , May 24, 2016 ... beide primären Endpunkte und ... Überlegenheit in ‚ausgezeichneter plus guter ... Colons    ,      (Logo: ... gab heute neue positive Daten von der MORA-Studie ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... On Memorial Day, ... who lost their lives in military battle for the country. The nonprofit Hope ... to provide more programs that empower independence for disabled military veterans, as well as ...
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent Pharma ... drugs, biologics, consumer health and global clinical supply services, today announced two key ... the company’s continued investment and strategic growth plans in the Asia Pacific region. ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... chain solutions, today announced the organization has earned its ISO 13485 certification, indicating ... is compliant with all rules and policies associated with ISO quality standard 13485. ...
(Date:5/26/2016)... ... May 26, 2016 , ... American orthopedic surgeon ... officer of Blue Horizon International (BHI), Brian Mehling, M.D., spoke at an International ... May 5-6, 2016 in Chicago, IL, USA. Dr. Mehling’s presentation was focused on ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... oncology professionals, has added National Cancer Institute-designated University of Virginia (UVA) Cancer ... this new partnership, OncLive’s editorial and marketing teams will publicize and promote public ...
Breaking Medicine News(10 mins):